FDA Medical Device Adverse Reports Found Inaccurate

A study reveals significant errors and reporting delays in medical device safety documentation submitted to federal regulators.

Updated on Oct. 22, 2026 in Healthcare

Bold flat-color editorial illustration of a surgical probe, symbolizing the clinical and regulatory oversight challenges in medical device safety reporting. — A new study reveals that thousands of adverse event reports in the FDA's MAUDE database are incomplete or inaccurate, obscuring medical device safety. AI Illustration. Upload story photo >

Live Poll

Should medical device companies face stricter oversight for reporting safety data to federal regulators?

New research shows that thousands of medical device adverse event reports in the FDA MAUDE database contain incomplete or inaccurate data. The findings indicate widespread non-compliance with reporting standards, leading to a significant undercounting of safety incidents.

Why it matters

The systematic failure to accurately document and report adverse events obscures the true risk profile of medical devices used in clinical settings. This breakdown undermines the FDA's ability to monitor device performance and ensure patient safety nationwide.

Analysis of 6,308 summary reports revealed that 57 percent failed to identify a specific device problem, while 55 percent missed the 30-day reporting deadline. These errors contributed to a total undercount of 11,902 adverse events.

The players

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical devices.

The BMJ

The British Medical Journal is a weekly peer-reviewed medical trade journal that publishes research and analysis on public health and clinical practice.

The details

Researchers found that 91 percent of the adverse events analyzed involved class 3 high-risk devices, yet nearly 40 percent of reports selected the vague 'insufficient information' label. Further investigation into the MAUDE database confirms that annual summary reporting volume grew by a factor of 1.21 between 2020 and 2024.

July 2019 through June 2025: Period covered by the study of the MAUDE database.
2020 to 2024: Period during which annual summary reporting increased by a factor of 1.21.
Oct. 14, 2026: Publication date of the findings in The BMJ.

Market Landscape

This study highlights a major failure to meet the FDA's 30-day adverse event reporting requirement, signaling systemic gaps in post-market surveillance. Such inaccuracies complicate the competitive landscape by masking the safety performance of high-risk medical devices.

Patients and healthcare providers should be aware that the official data on device complications may be less comprehensive than federal reports suggest. Clinicians are encouraged to maintain vigilance when tracking device performance in their own practice.

The takeaway

Reliable data is essential for effective medical device regulation and informed clinical decision-making. Stakeholders should prioritize improvements in data transparency to ensure that safety documentation truly reflects real-world performance.